Introduction {#s1}
============

γ-Aminobutyric acid (GABA) is the major inhibitory amino acid neurotransmitter in the vertebrate nervous system. The fast synaptic inhibition is mediated by the opening of a chloride channel formed by the GABA~A~ receptors. The GABA~A~ receptors are also clinically relevant drug targets for anti-convulsant, anxiolytic and sedative-hypnotic agents. Subtypes of GABA~A~ receptors are assembled from pentameric combinations of α~1~-α~6~, β~1~-β~3~, γ~1~-γ~3~, ρ~1~-ρ~3~, ε, δ and π subunits [@pone.0006977-Korpi1], [@pone.0006977-Whiting1]. The molecular heterogeneity of GABA~A~ receptor subunits is further increased by the alternative splicing of some subunit mRNAs, producing at least two isoforms of each of the α~6~, β~2~, β~3~ and γ~2~ subunits [@pone.0006977-Mehta1]. Most GABA~A~ receptors are composed of two α subunits, two β~2~ subunits and one γ subunit [@pone.0006977-Whiting2]. The β~2~ subunit gene products of human *GABRB2* expressed from cDNA library are found in two alternatively spliced isoforms, the short form β~2S~ and the long form β~2L~. The inclusion of an extra 38-amino acid Exon 10 in β~2L~ but not in β~2S~ in an intracellular loop brings with it a potential phosphorylation site at Thr^365^ for calmodulin-dependent protein kinase II ([Figure 1A](#pone-0006977-g001){ref-type="fig"})[@pone.0006977-McKinley1].

![Characterizations of Exon 10 of *GABRB2*.\
(A) The exonic structure of human *GABRB2* showing positions of the tagging SNPs, and the alignment of its Exon 10 with corresponding sequences in other vertebrates (from UCSC Genome Browser). The lengths of the sequences corresponding to the intervening sequences between E9 and E11 in the different species are indicated on the right. Dots represent identities; single line, deletions; double-dashed line,unalignable bases. Exons are shown as numbered boxes. (B) RT-PCR analyses of Exon 10 expressions from rat, mouse, human and monkey brain cDNA libraries with the common forward primer F2 against Exon 9 and reverse primer R4.2 against Exon 10 ([Table S4](#pone.0006977.s011){ref-type="supplementary-material"}). (C) GABA-potentiated current rundowns of GABA~A~ receptors containing α~1~, γ~2~ and β~2L-T365A~. (D) The measured currents upon successive additions of GABA expressed as % of the peak current elicited by the first addition of GABA. Significantly different responses between the α~1~β~2L-T365A~γ~2L~ (▾) and α~1~β~2L~γ~2L~ (□) receptors are marked by single (*P*\<0.05) or double (*P*\<0.01) asterisks. (E) Same as part D with 4 mM ATP infusion.](pone.0006977.g001){#pone-0006977-g001}

Schizophrenia (SCZ) and bipolar disorder (BPD) are major psychotic disorders with a significant genetic component in their complex etiology [@pone.0006977-Craddock1]. *GABRB2*, which encodes the β~2~ subunit of GABA~A~ receptors, contains single nucleotide polymorphisms (SNPs) in non-coding sequences in the Intron 8-Intron 9 region that have been associated with SCZ [@pone.0006977-Lo1]--[@pone.0006977-Petryshen1]. Moreover, the expressions of β~2S~ and β~2L~ mRNA were found to be differentially decreased in the dorsolateral prefrontal cortex (DLPFC) of SCZ brains by real-time quantitative PCR, and these altered expressions were correlated with the SCZ-associated SNPs rs1816071 and rs1816072 in SCZ subjects carrying the heterozygous genotypes [@pone.0006977-Zhao1]. Since GABA~A~ receptors containing β~2L~ underwent a steeper current run-down than those containing β~2S~ under conditions of ATP depletion induced by repeated GABA-stimulation [@pone.0006977-Zhao1], these findings pointed to relationships between the alternate splicing of the Exon 10 region with both GABA current regulation and schizophrenia. It is therefore the objective of the present study to examine the factors determining the alternative splicing of Exon 10, and how the different β~2~ isoforms might be correlated with the major psychotic disorders.

Results {#s2}
=======

Variability of Exon 10 splicing in vertebrates {#s2a}
----------------------------------------------

Based on sequence alignments, Exon 10 is readily identified in mammals and lizard, but not in chicken, frog (*X. tropicalis*) or fishes ([Figure 1A](#pone-0006977-g001){ref-type="fig"}). In contrast, Exon 9 and Exon 11 are present in all of these vertebrate species ([Figure S1](#pone.0006977.s001){ref-type="supplementary-material"}). Notably, expressions of Exon 10 have been reported for both humans [@pone.0006977-McKinley1] and chicken [@pone.0006977-Harvey1], [@pone.0006977-Harvey2], even though the Exon 10 sequence expressed in chicken bears little resemblance to that in mammals. In the present study, expression of Exon 10 was detected in rhesus monkey and mouse brains but not in rat brain ([Figure 1B](#pone-0006977-g001){ref-type="fig"}). The full-length β~2L~ coding sequences amplified from monkey and mouse brain cDNA libraries also confirmed the presence of β~2L~ in these two species ([Figure S2](#pone.0006977.s002){ref-type="supplementary-material"}). Thus there exist considerable variations among the vertebrates with respect to Exon 10 expression.

The species variations in Exon 10 expression are paralleled by variations in the length of the intervening gene segment between Exon 9 and Exon 11([Figure 1A](#pone-0006977-g001){ref-type="fig"}, right), which increases from \<3,000 bp in the fishes to 14,000--19,000 bp in non-mammalian land vertebrates, and \>28,000 bp in marsupial and placental mammals. Furthermore, this region of the gene is readily blocked by RepeatMasker, which identifies DNA sequences containing interspersed repeats and low sequence complexity [@pone.0006977-Jurka1]. This suggests that insertions and expansions of repeat elements could be a significant contributing factor to the sharp increase in Exon 9-Exon 11 length from the lower vertebrates to the higher vertebrates. In fact, the sequence from 85-bp upstream to 66-bp downstream of Exon 10 has been annotated as a candidate LINE3, viz. a member of the Long Interspersed Nucleotide Element family (UCSC GenomeBrowser: <http://genome.ucsc.edu/cgi-bin/hgTracks>). Evolutionary changes in the lengths of the gene segments corresponding to the other human introns in *GABRB2* are shown in [Figure S3](#pone.0006977.s003){ref-type="supplementary-material"}. Since only gene but not cDNA sequences are available in various non-human species, their exact exonic structures yet remain to be ascertained.

Expressions of human Exon 10 region from minigenes {#s2b}
--------------------------------------------------

In order to identify some of the effects of intronic sequences flanking Exon 10 on the splicing of the region between Exon 9 and Exon 11, minigene constructs containing Exons 2--9, a varying length of Intron 9, Exon 10, an shortened Intron 10, and Exon 11 were constructed and expressed in Human embryonic kidney (HEK) 293 cells ([Figure 2](#pone-0006977-g002){ref-type="fig"}). This wild-type (WT) minigene construct containing a full length Intron 9, was unfavorable toward the generation of Exon 10, as indicated by the absence of a significant Exon 10-containing Band II DNA in the WT gel slot (Lane 2, [Figure 2A](#pone-0006977-g002){ref-type="fig"}). Similarly, the Δ1, Δ3, Δ6, Δ7 and Δ8 minigenes, each containing a shortened Intron 9, also did not give rise to any Band II DNA. Surprisingly, when the sequence between bp 1,451 and 3,513 in Intron 9 was further deleted from Δ1 to yield Δ2, a significant Exon 10-containing Band II was obtained, along with a Band I which contained a novel Exon 10a consisting of two segments of base sequences located between the E9 and E10 sequences ([Figure 2B](#pone-0006977-g002){ref-type="fig"} and [Figure S4](#pone.0006977.s004){ref-type="supplementary-material"}). When Δ2 underwent a further shortening of Intron 9 in the direction toward Exon 9 to yield Δ3, removing 451 bases including the rs187269 SNP site, both Exon 10 and Exon 10a disappeared. With still further shortening of Δ3 to yield Δ4, a different novel Exon 10b appeared in the form of Band IV. Shortening of Δ4 to yield Δ5 led to a re-emergence of the Exon 10-containing Band II along with a novel Exon 10c in the form of Band III. These observed exonal variations encoded by minigenes WT and Δ1--Δ8 pointed to the complexity of Exon 10 expression, in keeping with the relative ease of generation of new splicing forms in this region.

![Effects of intronic sequences on Exon 10 expression in minigene constructs.\
(A) Minigenes of human *GABRB2* and their expressions in transfected cells. Left panel shows the structures of the minigenes; right panel shows the RT-PCR products amplified, using primers F2 and R0, from RNA derived from human brain or from minigene transfected-cells. Minigene WT consisted of E2-9, I9, E10, I10 (with a deletion ranging from 1208 bp downstream of E10 to 1126 bp upstream of E11, as indicated by the gap), and E11. Minigenes Δ1--Δ8 each carried a further deletion (shown as a gap) within I9. The determined sequences of Bands I--V are shown in [Figure S4](#pone.0006977.s004){ref-type="supplementary-material"}. (B) The proposed splicing origins of Bands I--V. Band II contained \[3′portion of E9\]-\[E10\]-\[5′portion of E11\]; Band V contained \[3′portion of E9\]-\[5′portion of E11\]. Band I contained the 3′-portion of E9, a replacement of E10 by E10a, which was derived from a joining of the two grey boxes, plus the 5′-portion of E11; Band III contained the 3′-portion of E9, a replacement of E10 by E10b derived from a joining of the two grey boxes, plus the 5′-portion of E11; Band IV was similar to Band I, except that one of the two grey boxes was different. The dotted bent lines between adjacent exons indicate fusion brought about by splicing, and the solid bent lines indicate fusion brought about by deletion in the minigene construct.](pone.0006977.g002){#pone-0006977-g002}

Identification of potential isoforms from human brain cDNA {#s2c}
----------------------------------------------------------

The results described in [Figure 2](#pone-0006977-g002){ref-type="fig"} revealed splicing variants that generated three novel exons from the minigenes Δ2, Δ4 and Δ5: Exon 10a from Δ2, Exon 10b from Δ4, and Exon 10c from Δ5. In view of this observed propensity of the Exon 9-Exon 11 region to give rise to these novel exons in minigene transfected cells, it becomes of interest to determine whether the novel exons of this kind might also be expressed in the human brain. Accordingly, a human brain cDNA library (Resgen, Invitrogen) was PCR-amplified with primers F1 (forward), and R1, R2, R3, R4 and R5 (reverse) designed to amplify such novel exons, as illustrated in [Figure 2B](#pone-0006977-g002){ref-type="fig"} and [Figure 3A](#pone-0006977-g003){ref-type="fig"}. The amplified PCR products shown in [Figure 3B](#pone-0006977-g003){ref-type="fig"} were cloned into the pMD-18T vector and sequenced. The sequencing results in [Figure 3C](#pone-0006977-g003){ref-type="fig"} showed that the Lane 1, Lane 2 and Lane 3 DNAs were all derived from a cDNA encoding a novel isoform β~2S1~ that spanned from the F1 primer to a point between the R3 and R4 primers. The absence of a visible DNA band in Lane 4 indicated the lack of significant F1-R4 PCR product. In Lane 5, a F1-R5 PCR reaction gave rise to three distinct DNA sequences corresponding to the known long (β~2L~) and short (β~2S~) isoforms together with a novel isoform β~2S2~.

![Novel splicing isoforms of the human GABA~A~ receptor β~2~ subunit.\
(A) Exonal structures of four different β~2~ subunit isoforms in human brain. Line 1 shows *GABRB2* structure with exons indicated by boxes (shaded for coding regions, and unshaded for non-coding regions). Lines 2--5 show the exonal compositions of alternatively spliced forms of β~2~. (B) EB-stained PCR products amplified from human brain cDNA library. Lane M, DNA standards; Lanes 1--5, PCR products obtained using forward primer F1 with reverse primers R1- R5 ([Table S4](#pone.0006977.s011){ref-type="supplementary-material"}), respectively. (C) Alignment of the cDNA sequences of the four isoforms. Base-pair numbering was based on β~2L~ cDNA. Bases in uppercase represent coding sequences, and those in lowercase represent non-coding sequences. Exons E2-E12 are shown in alternating shaded/unshaded backgrounds. The dotted lines represent intervening sequences that are not shown in detail. The dashed lines represent gapped/absent sequences. The start-codon ATG and stop-codons TAG or TAA are boxed. The italicized *GAC* spanning bp 1228--1294 incorporated a frame-shift that generated a 3′ TAG termination codon for β~2S2~. The fourth transmembrane domain (TM4) is marked in part A and underlined in part C. (D) The expression levels of β~2S~, β~2S2~, β~2S1~ and β~2L~ in different human brain regions relative to β~2S~ level in cerebral cortex were determined by means of real-time PCR. The amounts of different isoforms in the cerebral cortex (grey columns) relative to β~2S~ were: β~2S2~, 0.47; β~2S1~, 0.06; and β~2L~ 0.03. (E) Surface location of recombinant GABA~A~ receptors containing different β~2~ subunits (scale bars = 10 µm).](pone.0006977.g003){#pone-0006977-g003}

The mRNA of the novel isoform β~2S1~, defined by the PCR primers F1 and R3, was at least 2,470 bp in length. It contained a 3′-extended Exon 9 from Intron 9 retention and was devoid of Exons 3, 10 and 11, resulting in a 314-amino acid polypeptide. In contrast, the mRNA of β~2S2~ was at least 1,362 bp in length, was devoid of Exon 10, and contained an Exon 11 shortened by a 64-bp deletion that brought about a frameshift-generated TAG to result in a 373-amino acid polypeptide ([Figure 3C](#pone-0006977-g003){ref-type="fig"}). [Figure 3D](#pone-0006977-g003){ref-type="fig"} shows the relative mRNA expression levels of β~2S1~ and β~2S2~ in different human brain regions. Their relative amounts in the cerebral cortex were: β~2S~\>β~2S2~\>\>β~2S1~\>β~2L~.

Electrophysiological properties of recombinant receptors {#s2d}
--------------------------------------------------------

The cell surface location of recombinant GABA~A~ receptors containing different isoforms of β~2~ together with α~1~ subunits upon expression in HEK293 cells was indicated by immunofluorescence staining ([Figure 3E](#pone-0006977-g003){ref-type="fig"}). The electrophysiological responses of these receptors to GABA stimulation are shown in [Figure S5A](#pone.0006977.s005){ref-type="supplementary-material"}. The half-maximal GABA effective concentration (EC~50~) of the α~1~β~2~-myc receptors containing different isoforms of β~2~ ranged from 2.5--3.4 µM ([Table 1](#pone-0006977-t001){ref-type="table"} and [Figure S5B](#pone.0006977.s005){ref-type="supplementary-material"}).

10.1371/journal.pone.0006977.t001

###### Electrophysiological parameters of splicing isoforms.

![](pone.0006977.t001){#pone-0006977-t001-1}

  Isoform           N   EC~50~(µM)   Hill coefficient   I~max~(nA)
  ---------------- --- ------------ ------------------ ------------
  α~1~β~2S~-myc     5    2.5±0.3         1.8±0.4          867±83
  α~1~β~2S1~-myc    8    2.6±0.1         2.0±0.2          696±90
  α~1~β~2L~-myc     6    3.1±0.3         1.8±0.2          877±69
  α~1~β~2S2~-myc    9    3.4±0.2         1.7±0.2          730±43

N represents the cell number employed in each assay. The values shown are mean ± standard error.

Previously it was found that upon repeated GABA-stimulations, GABA~A~ receptors containing β~2L~ displayed a greater current run-down compared to those containing β~2S~ [@pone.0006977-Zhao1]. Since Thr^365^, a potential phosphorylation site for calmodulin dependent protein kinase II, is present in β~2L~ but not β~2S~, its possible involvement in current run-down was examined by a Thr365Ala mutation to yield the mutant construct β~2L-T365A~. When repeated receptor activation was induced by exposure of cells transiently expressing α~1~β~2L-T365A~γ~2L~, α~1~β~2L~γ~2L~ or α~1~β~2S~γ~2L~ to 300 µM GABA in the absence of ATP infusion ([Figure 1C](#pone-0006977-g001){ref-type="fig"}), [Figure 1D](#pone-0006977-g001){ref-type="fig"} show that the 64.3% run-down reduction relative to initial current displayed by the β~2L-T365A~-containing receptors was smaller than the 77.3% reduction displayed by the wildtype β~2L~-containing receptors, and practically the same as the 64.0% reduction displayed by the β~2S~-containing receptors. These findings suggest that the greater sensitivity of α~1~β~2L~γ~2L~ relative to α~1~β~2S~γ~2L~ toward current run-down is caused by the depletion of intracellular ATP affecting the phosphorylation status of Thr^365^. In keeping with this, addition of 4 mM ATP to the intracellular infusate reduced the run-down amplitudes of all three kinds of receptors, and effectively narrowed the differences between them ([Figure 1E](#pone-0006977-g001){ref-type="fig"} and [Figure S6](#pone.0006977.s006){ref-type="supplementary-material"}).

Genetic correlations with isoform expressions in psychotic disorders {#s2e}
--------------------------------------------------------------------

Expressions of the four isoforms β~2L~, β~2S~, β~2S1~ and β~2S2~ in DLPFC of postmortem CON, SCZ and BPD brains were determined using quantitative real-time PCR, and normalized by the geometric mean of the three reference genes glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*), ubiquitin C (*UBC*) and hydroxymethyl-bilane synthase (*HMBS*) as described [@pone.0006977-Zhao1]. The levels of β~2S1~ were significantly increased in both SCZ (by 43.0%, *P~LRS~* = 0.038) and BPD (by 43.7%, *P~LRS~* = 0.031) ([Figure 4A](#pone-0006977-g004){ref-type="fig"}), whereas the levels of β~2S2~ were significantly decreased in both SCZ (by 17.9%, *P~LRS~* = 0.036) and BPD (by 22.6%, *P~LRS~* = 0.034). All these cases also passed the global significance test with 1,000 permutations. These observations on β~2S1~ and β~2S2~ were compared to earlier results on β~2S~ and β~2L~ [@pone.0006977-Zhao1] in [Figure 4A](#pone-0006977-g004){ref-type="fig"}, which showed that the mean expression levels of all four isoforms in SCZ deviated significantly from the CON levels. The mean expression levels in BPD deviated from the CON levels for β~2S1~ and β~2S2~, but not for β~2S~ and β~2L~. When the sample characteristics of gender, age, brain pH, postmortem interval (PMI), and sample refrigeration interval (RFI) were included individually as a covariate in UNPHASED analysis, the Wald test indicated no significant covariate effect on β~2S1~ or β~2S2~ expression.

![Correlations of isoform expressions with disease and genotype.\
(A) Expressions of β~2L~, β~2S~, β~2S1~ and β~2S2~ in SCZ and BPD relative to CON. The mean expressions of each of the four isoforms in SCZ are represented by shaded columns, and the mean expressions in BPD by clear columns. The CON level is represented by the horizontal dashed line. Significant deviations (*P*\<0.05) of mean expressions in SCZ or BPD from CON, examined using UNPHASED, is marked by \* above columns. Relative expressions of β~2S1~ (part B) and β~2S2~ (part C) are shown for the homozygous-major MM (grey), heterozygous Mm (white), and homozygous-minor mm (hatched) genotypes of the tagging SNPs rs1816071, rs2546620, rs187269, and rs34104385 in the male CON, SCZ and BPD cohorts. Standard errors are indicated by bars. Expression levels in BPD or SCZ that deviated significantly from CON based on ANOVA with LSD *post hoc* test are marked by \* above the indicated comparison. Any expression level of Mm or mm that deviated significantly from MM within the diagnostic group is marked by \#. Any expression level of mm that deviated significantly from both MM and Mm is marked by∇. After additional testing by the Bonferroni *post hoc* test, those cases remaining significant (*P*\<0.05) were marked as circled \*, \# or ∇.](pone.0006977.g004){#pone-0006977-g004}

Previously the SNPs and haplotypes in the Intron 8-Intron 9 region ([Figure S7](#pone.0006977.s007){ref-type="supplementary-material"}) have been associated with SCZ [@pone.0006977-Lo2], [@pone.0006977-Zhao1]. The results in [Table S1](#pone.0006977.s008){ref-type="supplementary-material"} extended their associations to BPD. Correlation analysis between the four isoform expressions and different alleles, haplotypes and genotypes of the six tagging SNPs in the combined CON-BPD-SCZ cohorts revealed significant correlations for β~2L~ or β~2S~ at the allelic, genotypic as well as haplotypic levels ([Table 2](#pone-0006977-t002){ref-type="table"}). When the males were analyzed in separation from the females, comparable significant correlations were also observed with β~2S2~ expression. The various effects relating to isoform expressions involved particularly the tagging-SNPs rs1816071, rs252944, rs187269, and rs34104385, all of which were significantly associated with both BPD ([Table S1](#pone.0006977.s008){ref-type="supplementary-material"}) and SCZ [@pone.0006977-Lo2], [@pone.0006977-Zhao1].

10.1371/journal.pone.0006977.t002

###### The relationships of alleles, genotypes and haplotypes with isoform expressions in the combined CON, BPD and SCZ cohorts.

![](pone.0006977.t002){#pone-0006977-t002-2}

                rs1816071   rs2546620   rs13178374   rs252944   rs187269   rs34104385   Male+Female     Male                                                     
  ------------ ----------- ----------- ------------ ---------- ---------- ------------ ------------- ----------- ------- ------- ----------- ----------- ------- -----------
  Alleles         **X**                                                                  **0.010**    **0.010**   0.833   0.080   **0.005**   **0.005**   0.929   **0.002**
                                                                 **X**                   **0.046**      0.055     0.860   0.084   **0.027**   **0.023**   0.720   **0.010**
  Genotypes       **X**                                                                  **0.023**    **0.024**   0.883   0.147   **0.016**   **0.021**   0.960   **0.005**
                                                      **X**                              **0.030**    **0.019**   0.680   0.056     0.192       0.252     0.542     0.192
                                                                 **X**                   **0.041**      0.045     0.827   0.151     0.053       0.065     0.918   **0.022**
  Haplotypes      **X**       **X**                                                      **0.032**    **0.035**   0.966   0.127   **0.018**   **0.018**   0.733   **0.005**
                  **X**                   **X**                                          **0.033**    **0.036**   0.960   0.161   **0.018**     0.019     0.672   **0.006**
                  **X**                               **X**                              **0.031**    **0.030**   0.500   0.184   **0.013**   **0.017**   0.706   **0.004**
                  **X**                                          **X**                     0.080        0.081     0.936   0.320     0.039       0.043     0.884   **0.013**
                  **X**                                                      **X**       **0.006**      0.036     0.305   0.272   **0.002**   **0.022**   0.256   **0.012**
                              **X**                              **X**                     0.130        0.160     0.861   0.093     0.088       0.076     0.848   **0.032**
                                          **X**                  **X**                     0.097        0.092     0.981   0.221   **0.029**     0.092     0.750   **0.019**
                                          **X**                              **X**         0.582        0.275     0.792   0.459     0.457       0.327     0.599   **0.025**
                                                                 **X**       **X**       **0.019**      0.123     0.339   0.244   **0.008**     0.073     0.337     0.062

The X in each column indicates the SNP-composition of the one-SNP alleles, genotypes, or two-SNP haplotypes in the combined CON, BPD and SCZ cohorts in that row. *P~LRS~*-values shown in the table were obtained from the likelihood ratio test for correlations between allele or haplotype on the one hand, and expression of β~2L~, β~2S~, β~2S1~ or β~2S2~ on the other. Global tests with 1000 permutations were applied to all the significant cases (*P* ~LRS~\<0.05) to yield *P* ~Glob~, and only those *P* ~LRS~ values that yielded both *P* ~LRS~\<0.05 and *P* ~Glob~\<0.05 are shown in bold font in the Table.

The relationships between isoform expressions and individual genotypes of the six tagging SNPs were further analyzed in the male samples using ANOVA both between and within diagnostic groups ([Figure 4B--4C](#pone-0006977-g004){ref-type="fig"} and [Table S2](#pone.0006977.s009){ref-type="supplementary-material"}). The interdiagnostic group comparisons with LSD tests showed that the MM genotypes of rs1816071 (*P* = 0.017) and rs187269 (*P* = 0.009) significantly increased β~2S1~ in BPD relative to CON ([Figure 4B](#pone-0006977-g004){ref-type="fig"}, indicated by \*). On the other hand, the Mm genotypes of rs1816071 (*P* = 0.028), rs2546620 (*P* = 0.010) and rs34104385 (*P* = 0.047) significantly reduced β~2S2~ in SCZ, and the Mm genotypes of rs2546620 (*P* = 0.037), rs187269 (*P* = 0.004) and rs34104385 (*P* = 0.047) significantly reduced β~2S2~ in BPD ([Figure 4C](#pone-0006977-g004){ref-type="fig"}, indicated by \*). When additionally tested by the Bonferroni *post hoc* test, the significant correlations between MM of rs187269 and increased β~2S1~ in BPD, between Mm of rs2546620 and decreased β~2S2~ in SCZ, and between Mm of rs187269 and decreased β~2S2~ in BPD, all remained significant at *P*\<0.05 (as indicated by circled \* in [Figure 4B--4C](#pone-0006977-g004){ref-type="fig"}).

The intradiagnostic group comparisons showed that in the BPD cohort, the Mm genotype of rs187269 significantly decreased β~2S1~ expression relative to the MM genotype (*P* = 0.022) ([Figure 4B](#pone-0006977-g004){ref-type="fig"}, indicated by \#); the mm genotype of rs1816071 significantly decreased β~2S2~ expression relative to MM (*P* = 0.026) ([Figure 4C](#pone-0006977-g004){ref-type="fig"}, indicated by \#); and the Mm (*P* = 0.004) and mm (*P* = 0.033) genotypes of rs187269 both significantly decreased β~2S2~ expression relative to MM. In the SCZ cohort, the mm genotype of rs1816071 significantly decreased β~2S2~ expression relative to MM (*P* = 0.029); the Mm genotype of rs2546620 significantly decreased β~2S2~ expression relative to MM (*P* = 0.044); and the mm genotypes of rs187269 and rs34104385 both significantly decreased β~2S2~ expression relative to the MM as well as Mm genotypes (all *Ps*\<0.05) ([Figure 4C](#pone-0006977-g004){ref-type="fig"}, indicated by∇). When additionally tested by the Bonferroni *post hoc* test, some of these correlations remained significant at *P*\<0.05 (as indicated by circled \# or ∇ in [Figure 4C](#pone-0006977-g004){ref-type="fig"}). Various *P* values are given in [Table S2](#pone.0006977.s009){ref-type="supplementary-material"}.

Discussion {#s3}
==========

Novel isoforms in a splicing hot-spot {#s3a}
-------------------------------------

The β~2~ subunit polypeptide of the GABA~A~ receptors, encoded by up to eleven exons, is known to exist in different isoforms: β~2L~ which contains Exon 10, and β~2S~ which is devoid of Exon 10 [@pone.0006977-McKinley1]. Since the β~2L~ and β~2S~ expressions are associated with SCZ, and also produce different effects on GABA~A~ receptor run-downs, they could provide a fundamental link between *GABRB2* genotypes and physiological perturbations in schizophrenia [@pone.0006977-Zhao1], [@pone.0006977-Lo3]. In the minigene system, while minigene Δ2 gave rise to an Exon 10-containing Band II and an Exon 10a-containing Band I, a shortening of Δ2 to Δ3 that included the removal of the gene expression-correlated and schizophrenia-associated SNP rs187269 [@pone.0006977-Lo2] abolished both Band II and Band I. Likewise, other minigene deletions gave rise to Exon 10b (expressed from Δ4) and Exon 10c (expressed from Δ5). These findings pointed to the facile occurrence of different splicing modes in the Exon 9-Exon 11 segment in response to intron sequence variations. They prompted a search among human brain cDNAs for novel splicing products and led to the discovery of the two novel β~2~ isoforms β~2S1~ and β~2S2~ in the brain. In the β~2S1~ isoform, Exon 9 is extended through Intron 9 retention, and both Exons 3, 10 and 11 were omitted ([Figure 3A](#pone-0006977-g003){ref-type="fig"}). In the β~2S2~ isoform, Exon 10 is omitted, and Exon 11 is shortened by a 64-bp deletion that brought about a frameshift-generated TAG. The absence of Exon 11 from β~2S1~ and β~2S2~ implies the loss of the C-terminal transmembrane domain TM4 from these β~2~ isoforms. Functionally, the different β~2~ isoforms displayed non-identical EC~50~ values. Since the EC~50~ values of β~2S~ (containing Exon 11) and β~2S1~ (devoid of Exon 11) were not greatly different, Exon 11 and its constituent TM4 domain might not be an important determinant of EC~50~. Similarly, since the EC~50~ of β~2L~ (containing Exon 10) was also not greatly different from those of β~2S~, β~2S1~ and β~2S2~ (all devoid of Exon 10), Exon 10 also might not be an important determinant of EC~50~. That the β~2S2~ isoform was not detected earlier was likely due to its similar size as β~2S~, differing only by 64-bp, such that β~2S2~ was only found through screening of individual clones bearing RT-PCR products. The β~2S1~ isoform on the other hand has hitherto escaped detection probably because it became detectible only using PCR primers suggested by the minigene results.

The existence of as many as four isoforms, viz. β~2S~, β~2S2~, β~2S1~ and β~2L~ arising from alternative splicings of the Exon 10 region suggests that this region represents an 'alternative-splicing hotspot'. The brain-region distributions of β~2S~, β~2L~ and β~2S2~ were largely similar whereas that of β~2S1~ was more dissimilar. Exons 10a, 10b and 10c, which were expressed only by minigenes (viz. Δ2, Δ4 and Δ5 respectively) that carried a deletion in Intron 9, were not detected in the brain.

Relationships between novel isoforms and psychotic disorders {#s3b}
------------------------------------------------------------

Based on the six tagging SNPs in the Intron 8-Intron 9 segment, the results in [Table 2](#pone-0006977-t002){ref-type="table"} showed that the expression of the novel β~2S2~ isoform participated, at least among the males, along with the expressions of β~2S~ and β~2L~ in a number of allelic, genotypic and haplotypic correlations. As shown in [Figure 4A](#pone-0006977-g004){ref-type="fig"}, the expressions of all four isoforms in SCZ deviated significantly from CON, and this was also the case with β~2S1~ and β~2S2~ in BPD. Thus a derangement in β~2~ isoform expressions represents an important characteristic common to these two major psychotic disorders.

The genotypic effects recorded for the MM, Mm and mm genotypes of rs187269 in [Figure 4B](#pone-0006977-g004){ref-type="fig"} showed generally higher levels in the male BPD and SCZ cohorts compared to CON in agreement with the overall increases in β~2S1~ in BPD and SCZ ([Figure 4A](#pone-0006977-g004){ref-type="fig"}), with the positive correlations between β~2S1~ in BPD and genotype reaching the *P*\<0.05 significance level in the case of rs187269 MM ([Figure 4B](#pone-0006977-g004){ref-type="fig"}). On the other hand, the genotypic effects showed generally lower levels in the BPD and SCZ cohorts compared to CON in agreement with the overall decreases in β~2S2~ in BPD and SCZ ([Figure 4A](#pone-0006977-g004){ref-type="fig"}), with the negative correlations between β~2S2~ in SCZ and genotype reaching the *P*\<0.05 significant level in the case of the rs2546620 Mm and negative correlations between β~2S2~ in BPD and genotype also reaching the *P*\<0.05 significant level in the case of the rs187269 Mm ([Figure 4C](#pone-0006977-g004){ref-type="fig"}). Thus the observed increases in β~2S1~ expression in BPD in [Figure 4A](#pone-0006977-g004){ref-type="fig"} were led by increased expression by the MM genotype more so than any increased expression by the Mm or mm genotype, whereas the observed decreases in β~2S2~ expression in BPD and SCZ were led by decreased expression by the Mm genotype more so than any decreased expression by the MM or mm genotype. Correspondingly, such genotype-dependent alterations in β~2S2~ expression were supported by the statistically significant inter-genotype differences (marked by \# and ∇ in [Figure 4C](#pone-0006977-g004){ref-type="fig"}) observed in the BPD and SCZ cohorts, in contrast to the absence of such differences in the CON cohort.

In conclusion, β~2S1~ and β~2S2~, the two novel isoforms of GABA~A~ receptor β~2~-subunit discovered in the present study, shared two fundamental attributes with the previously known β~2S~ and β~2L~ isoforms: the expressions of all four were significantly correlated with not only SCZ or BPD or both, but also with the genotypes of SNPs in the Intron 8-Intron 9 region of the *GABRB2* gene. The present study therefore has rendered even more unambiguous the importance of the SNPs in this region of *GABRB2* with respect to isoform expressions and the etiologies of the two major psychotic disorders.

Materials and Methods {#s4}
=====================

DNA and RNA samples {#s4a}
-------------------

RNA was extracted from tissue culture cells using guanidine method [@pone.0006977-Chomczynski1]. Brain RNA samples from mouse, rhesus monkey, and different human brain regions were purchased from BioChain Institute. Postmortem brain DNA and RNA of 31 SCZ, 30 BPD and 31 CON were donated by the Stanley Collection ([Table S3](#pone.0006977.s010){ref-type="supplementary-material"}) [@pone.0006977-Torrey1]. After treatment with DNase I (Invitrogen), RNA was reverse transcribed to cDNA. Reaction was carried out with 2 µg of total RNA, random hexamers and TaqMan Reverse Transcription Kit (Applied Biosystems) for 10 min at 25°C, 30 min at 48°C, 5 min at 95°C.

Oligonucleotide primers and probes {#s4b}
----------------------------------

The primers for PCR, DNA sequencing and cloning, and probes of *GABRB2* isoforms and *GAPDH* for real-time PCR were designed using Primer Express 3.0 (Applied Biosystems Inc., Foster City, CA), as described in [Table S4](#pone.0006977.s011){ref-type="supplementary-material"}, and obtained from Proligo Singapore Pte Ltd. TaqMan Expression Assays (Applied Biosystems) were employed for *UBC* and *HMBS*.

Minigene construction {#s4c}
---------------------

A fragment that spanned from the start of Exon 9 to 1207 bp downstream of Exon 10 of *GABRB2* was amplified from human genomic DNA with the addition of a GC[TCTAGA]{.ul} sequence (where the underlined sequence represents an XbaI site) to its 3′ end. This amplified fragment was cloned into the pMD18-T vector to yield pMD18T-I. Another fragment spanning from 1127 bp upstream of Exon 11 to the end of Exon 11 of *GABRB2* was likewise amplified from human genomic DNA with the additions of a GC[TCTAGA]{.ul} (where the underlined sequence represents an XbaI site) to both its 5′ and 3′ terminals. This amplified fragment was cloned into the pMD18T-I via the XbaI site to yield pMD18T-I/II, such that the cloned insert contained sequentially Exon 9, Intron 9, Exon 10, a shortened Intron 10, and Exon 11. The insert in pMD18T-I/II was in turn digested out with ApaI (located in Exon 9) and Xho I (in Exon 11), and inserted into the corresponding sites in Exon 9 and Exon 11 of the pcDNA3.1-β~2S~ construct, which carries the coding region of β~2~ cDNA without any intron. The resultant human GABA~A~ receptor β~2~ minigene was designated as WT: it contained sequentially part of Exon 2, Exons 3--9 (coding region only and devoid of Introns 2--8), Intron 9, Exon 10, an Intron 10 shortened by a 29.6 Kb deletion (bp 160,655,142--160,684,744 inclusive on Chromosome 5) and Exon 11 ([Figure 2A](#pone-0006977-g002){ref-type="fig"}). A series of deletions of WT were performed using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) to yield Δ1 (with a deletion of bases 3513 to 3630 inclusive of Intron 9), Δ2 (with a deletion of bases 1451 to 3630 inclusive of Intron 9), Δ3 (with a deletion of bases 1000 to 3630 inclusive of Intron 9), Δ4 (with a deletion of bases 518 to 3630 inclusive of Intron 9), Δ5 (with a deletion of bases 72 to 3630 inclusive of Intron 9), Δ6 (with a deletion of bases 72 to 2818 inclusive of Intron 9), Δ7 (with a deletion of bases 72 to 1880 inclusive of Intron 9), and Δ8 (with a deletion of bases 72 to 981 inclusive of Intron 9). WT and its various deletions were transfected into HEK293 cells, and expression of *GABRB2* mRNA in the cells was monitored using RT-PCR using the primers located in Exon 9 and Exon 11.

Expression constructs {#s4d}
---------------------

The coding regions of the human GABA~A~ receptor α~1~, β~2S~, β~2L~ and γ~2L~ subunit cDNAs were amplified from human brain cDNA libraries (Resgen, Invitrogen), and individually cloned into the mammalian expression vector pcDNA3.1 (Stategene, USA) as described previously [@pone.0006977-Zhao1]. The site-directed mutant pcDNA3.1-β~2L-T365A~ was generated with the PCR-based Mutagenesis Kit from Stratagene. To facilitate protein detection, the Myc tag was fused into the C-terminal of the β~2L~, β~2S~, β~2S1~ and β~2S2~ subunits by cloning into pCI-neo-Myc expression vector (Promega). Briefly, the flanking restriction sites EcoR I and Xha I were added on respectively to the 5′ terminal and 3′ terminal of the β~2L~, β~2S~, β~2S1~ and β~2S2~ cDNAs by PCR amplification. After digestion with EcoR I and Xba I, the cDNAs were inserted into the corresponding sites in pCI-neo-Myc vector. The fidelity of the final expression constructs were verified by DNA sequencing.

Cell cultures and transfections {#s4e}
-------------------------------

HEK293 cells were maintained in Dulbecco\'s modified Eagle\'s medium supplemented by 10% fetal bovine serum (Invitrogen), and transfected using Lipofectamine & Plus reagents (Invitrogen) following the manufacturer\'s instructions. Transfection was performed either in 35 mm dishes with 3 µg/dish plasmid DNA, or in 12-well plates with 1.2 µg/well plasmid DNA. Cells were employed for RNA extraction, immunostaining and electrophysiology 48 h after transfection.

Properties of recombinant GABA~A~ receptors {#s4f}
-------------------------------------------

For immunostaining, cells plated on poly-L-lysine coated coverslips were fixed in paraformaldehyde. After blocking with bovine serum albumin and anti-Myc antibody (9E10 from mouse, diluted 1∶500), fluorescein-conjugated goat anti-mouse IgG (from goat and ditulted 1∶100; Molecular Probe) was applied, and immunostaining was examined using a Nikon TE2000E fluorescence microscope.

The recording of GABA dose-current responses in HEK293 cells containing recombinant receptors by means of whole-cell patch-clamping, and the induction of receptor run-down by repeated GABA-stimulations, was performed as described [@pone.0006977-Zhao1], [@pone.0006977-Nagata1]. Variation of current with GABA concentration was fitted to the Hill equation to estimate EC~50~ and Hill coefficient (n~H~).

Quantitative PCR and DNA sequencing {#s4g}
-----------------------------------

Quantitative real-time PCR was performed with TaqMan Probe as described [@pone.0006977-Zhao1] ([Table S4](#pone.0006977.s011){ref-type="supplementary-material"}). The geometric mean of three reference genes *GAPDH*, *HMBS* and *UBC* was employed for normalization of *GABRB2* expression [@pone.0006977-Vandesompele1].

Genotypes of various SNP and of a 12-bp sequence at rs34104385 were determined by sequencing of a PCR-amplified 4,469 bp segment spanning from 2,185 bp upstream to 2,039 bp downstream of Exon 9 of *GABRB2* ([Figure S7](#pone.0006977.s007){ref-type="supplementary-material"}), as described [@pone.0006977-Zhao1].

Statistical analysis {#s4h}
--------------------

Sequence alignments of *GABRB2* gene among different species were downloaded from UCSC Genome Browser website. Analyses of disease association of SNPs and two-SNP haplotypes, and analyses of correlations between isoform expression and disease status, allele, genotype or haplotype, were carried out with the likelihood ratio statistic (LRS) test to generate the *P* ~LRS~ value using UNPHASED program version 3.0.7 [@pone.0006977-Zhao1], [@pone.0006977-Dudbridge1]. Covariate analyses of demographic or clinical characteristics were performed using the Wald-test in UNPHASED v3.07; each case showing *P* ~LRS~\<0.05 was further evaluated by the LRS test with 1,000 permutations to generate a global *P~Glob~* value. Correlations between isoform expression and genotype were analyzed using ANOVA with LSD and Bonferroni *post hoc* tests in SPSS v11.5.

Supporting Information {#s5}
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Sequence alignments of (A) Exon 9 and (B) Exon 11 from different vertebrate species were downloaded from UCSC genome browser (<http://genome.ucsc.edu/cgi-bin/hgGateway>).
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Click here for additional data file.
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The full-length β~2L~ coding sequences from mouse (A) and monkey (B) brain cDNA libraries. RT-PCRs were performed with the three forward primers and three reverse primers given in [Table S4](#pone.0006977.s011){ref-type="supplementary-material"}, and the products were cloned into T-vector. The positive clones were validated by DNA sequencing.
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Intron sizes of *GABRB2* in vertebrate species.
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###### 

The cDNA sequences of Bands I, II, III, IV and V shown in [Figure 2](#pone-0006977-g002){ref-type="fig"} determined by cloning the cDNA in pMD-18T vector and sequencing. Band I cDNA was obtained from Δ2, Band II from human brain, Δ2 and Δ5, Band III from Δ5, Band IV from Δ4, and Band V from all of human brain, WT and Δ1-Δ8. The dashed arrows represent the PCR primer binding regions used in RT-PCR. The boxed sequences indicate the exon (Exon 10, Exon 10a, Exon 10b or Exon 10c) found in each instance between Exon 9 and Exon 11. There was no such exon in the case of Band V. The slash within the novel exons in I, III, IV indicates in each instance the gapped position in the minigene construct.
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###### 

GABA concentration-response currents (A) and curves (B) from transfected HEK293 cells expressing different isoforms of β~2~ together with α~1~ subunits. Recordings of representative current response of different doses of GABA are illustrated in part A. In part B, from left to right at 50% I~max~ (marked by horizontal dotted line): α~1~β~2S~-Myc, α~1~β~2S1~-Myc, α~1~β~2L~-Myc and α~1~β~2S2~-Myc, each representing the average estimate obtained with 5-9 cells through data fitted to the Hill equation.
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###### 

GABA-potentiated current rundowns of GABA~A~ receptors. Repeated GABA~A~ receptors activation was reduced by exposure of cells transiently expressing α~1~, γ~2~ plus one of the β~2L-T365A~, β~2L~, or β~2S~ to 300 µM of GABA in the presence of 4 mM of ATP infusion
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###### 

The positions of SNPs in the Intron 8-Intron 9 of *GABRB2* examined in the present study. SNP rs34104385 is a polymorphic site consisting of a 12-bp insertion-deletion variation (indel) followed by a A/C SNP, where the major A-allele is linked to the deletion form, and the minor C-allele is linked to the insertion form.
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###### 

*P* ~LRS~-values relating to association of single SNPs and two-SNP haplotypes of *GABRB2* with male BPD and SCZ cohort. The SCZ vs CON results, with the exception of those relating to rs34104385, were based on Ref. 11. The *P* ~LRS~-values shown were obtained with UNPHASED 3.07. Only those *P* ~LRS~\<0.05 further confirmed to be significant after 1,000 permutations are shown in bold font.
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###### 

Genotypic correlations with expressions of β~2S1~ and β~2S2~ in the male SCZ, BPD and CON cohorts. Genotypic effects of the tagging SNPs rs1816071, rs2546620, rs187269 and rs34104385 on β~2S1~ and β~2S2~ expressions are shown for the male SCZ, BPD and CON cohorts. N represents the number of samples of each of the three genotypes MM, Mm and mm. Overall genotypic effects on β~2S1~ and β~2S2~ expressions were assessed using ANOVA. Pair-wise genotype comparisons (MM vs. Mm, Mm vs. mm and MM vs. mm) were evaluated with LSD post hoc test in ANOVA, and the results were shown as *P* ~L~; the instances with *P* ~L~\<0.05 were further evaluated with Bonferroni post hoc test in ANOVA, and the results were shown as *P* ~B~. In all instances, *P*\<0.05 values are shown in bold font. The three Mean Ratios for each group refer to the expression level of, from top to bottom, the ratio of MM over Mm, Mm over mm, and MM over mm.
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###### 

Demographic and clinical information on subjects used in this study. Mean ± standard deviation; M, male; F, female; PMI, postmortem interval; BW, brain weight; RFI, duration of refrigerator storage; AOO, age of onset; TIH, time in hospital; DOI, duration of illness; LFPZ, lifetime of antipsychotic exposure in terms of fluphenazine equivalent in grams. ^a^35 CON, 35 SCZ and 35 BPD were provided by Stanley Research Foundation and 13 from three groups giving no RT-PCR products were excluded from this study. ^b^RNA sample obtained from BioChain Institute included one from rhesus monkey cortex, and 17 different human brain regions, with age of individual in parenthese: cerebral cortex (23), cerebellum (29), cerebral meninges (21), corpus callosum (27), diencephalon (29), postcentral gyrus (41), precentral gyrus (26), hippocampus (82), frontal lobe (41), occipital lobe (27), parietal lobe (26), temporal lobe (26), medulla oblongata (60), olfactory (87), pons (36), pituitary (53) and thalamus (71).
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Primers and probes used in this study. Restriction sites are underlined.
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